Brokerages Expect Oxford Immunotec Global PLC (NASDAQ:OXFD) Will Post Quarterly Sales of $20.37 Million

Wall Street brokerages expect that Oxford Immunotec Global PLC (NASDAQ:OXFD) will report $20.37 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Oxford Immunotec Global’s earnings. The lowest sales estimate is $20.13 million and the highest is $20.52 million. Oxford Immunotec Global posted sales of $16.05 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 26.9%. The business is expected to announce its next earnings report on Friday, November 8th.

On average, analysts expect that Oxford Immunotec Global will report full year sales of $72.13 million for the current year, with estimates ranging from $71.32 million to $72.57 million. For the next financial year, analysts expect that the business will report sales of $81.66 million, with estimates ranging from $81.02 million to $82.14 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Oxford Immunotec Global.

Oxford Immunotec Global (NASDAQ:OXFD) last announced its earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.07. The firm had revenue of $19.60 million during the quarter, compared to analyst estimates of $19.32 million. Oxford Immunotec Global had a net margin of 208.48% and a return on equity of 14.76%. Oxford Immunotec Global’s revenue was up 17.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.25) EPS.

Several research firms have recently weighed in on OXFD. BidaskClub lowered shares of Oxford Immunotec Global from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 10th. TheStreet lowered shares of Oxford Immunotec Global from a “c-” rating to a “d+” rating in a research report on Monday, July 15th. ValuEngine lowered shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Finally, Zacks Investment Research lowered shares of Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $18.00.

In other news, CEO Peter Wrighton-Smith sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $13.86, for a total transaction of $138,600.00. Following the completion of the transaction, the chief executive officer now owns 424,538 shares in the company, valued at approximately $5,884,096.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $19.90, for a total transaction of $59,700.00. The disclosure for this sale can be found here. Company insiders own 4.21% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its stake in Oxford Immunotec Global by 34.9% during the second quarter. Tower Research Capital LLC TRC now owns 2,734 shares of the company’s stock valued at $37,000 after buying an additional 708 shares in the last quarter. Aperio Group LLC purchased a new stake in Oxford Immunotec Global during the second quarter valued at about $42,000. BNP Paribas Arbitrage SA lifted its stake in Oxford Immunotec Global by 59,988.9% during the first quarter. BNP Paribas Arbitrage SA now owns 5,408 shares of the company’s stock valued at $93,000 after buying an additional 5,399 shares in the last quarter. C M Bidwell & Associates Ltd. purchased a new stake in Oxford Immunotec Global during the second quarter valued at about $93,000. Finally, Susquehanna International Group LLP purchased a new stake in Oxford Immunotec Global during the second quarter valued at about $162,000. 94.09% of the stock is owned by institutional investors.

OXFD traded down $0.08 on Thursday, reaching $14.12. The company had a trading volume of 111,400 shares, compared to its average volume of 168,681. The company has a fifty day moving average of $13.64 and a 200-day moving average of $14.84. The company has a market capitalization of $353.89 million, a P/E ratio of 27.69 and a beta of 0.37. The company has a current ratio of 13.35, a quick ratio of 12.76 and a debt-to-equity ratio of 0.03. Oxford Immunotec Global has a one year low of $11.88 and a one year high of $19.19.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

See Also: What are the benefits of a balanced fund?

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.